Giovan Giuseppe Di Costanzo1, Raffaella Tortora2, Filomena Morisco3, Luigi Addario2, Maria Guarino3, Gabriella Cordone2, Luigia Falco2, Nicola Caporaso3. 1. Department of Transplantation - Liver Unit, Cardarelli Hospital, Via A. Cardarelli 9, 80131, Naples, Italy. ggdicostanzo@libero.it. 2. Department of Transplantation - Liver Unit, Cardarelli Hospital, Via A. Cardarelli 9, 80131, Naples, Italy. 3. Department of Clinical Medicine and Surgery - Gastroenterology Unit, University of Naples "Federico II", Naples, Italy.
Abstract
BACKGROUND: Patients with diabetes are at increased risk of developing hepatocellular carcinoma (HCC) and have a poorer prognosis as compared to non-diabetics when HCC occurs. Diabetics with non-HCC cancers are at higher risk of toxicity related to systemic therapy, but data on HCC are lacking. OBJECTIVE: The aim of this study was to evaluate safety and effectiveness of sorafenib in HCC patients according to the presence/absence of diabetes. PATIENTS AND METHODS: From October 2008 to June 2014, 313 patients with HCC treated with sorafenib were enrolled. The patients were staged according to the BCLC system. Treatment response was evaluated according to the mRECIST criteria. The main evaluated outcomes were the overall survival and the safety in the two groups. RESULTS: Patients were divided in two groups: 80 diabetics (DIAB) and 233 nondiabetics (nDIAB). The median treatment duration was 4 months in DIAB and 3 months in nDIAB. Main adverse events occurred with comparable frequency in both groups, with the exception of rash, that was more frequent among DIAB than in nDIAB: 27.5 % vs 17.6 % (P = .047). The median overall survival was 9 months in nDIAB and 10 months in DIAB group (P = .535). Median time-to-progression (TTP) was longer the in DIAB than the nDIAB group (P = .038). CONCLUSIONS: Sorafenib was as safe as effective in DIAB and in nDIAB patients. The longer TTP observed among DIAB than in nDIAB patients might suggest a better anticancer effect of sorafenib in patients with diabetes.
BACKGROUND: Patients with diabetes are at increased risk of developing hepatocellular carcinoma (HCC) and have a poorer prognosis as compared to non-diabetics when HCC occurs. Diabetics with non-HCC cancers are at higher risk of toxicity related to systemic therapy, but data on HCC are lacking. OBJECTIVE: The aim of this study was to evaluate safety and effectiveness of sorafenib in HCC patients according to the presence/absence of diabetes. PATIENTS AND METHODS: From October 2008 to June 2014, 313 patients with HCC treated with sorafenib were enrolled. The patients were staged according to the BCLC system. Treatment response was evaluated according to the mRECIST criteria. The main evaluated outcomes were the overall survival and the safety in the two groups. RESULTS: Patients were divided in two groups: 80 diabetics (DIAB) and 233 nondiabetics (nDIAB). The median treatment duration was 4 months in DIAB and 3 months in nDIAB. Main adverse events occurred with comparable frequency in both groups, with the exception of rash, that was more frequent among DIAB than in nDIAB: 27.5 % vs 17.6 % (P = .047). The median overall survival was 9 months in nDIAB and 10 months in DIAB group (P = .535). Median time-to-progression (TTP) was longer the in DIAB than the nDIAB group (P = .038). CONCLUSIONS: Sorafenib was as safe as effective in DIAB and in nDIAB patients. The longer TTP observed among DIAB than in nDIAB patients might suggest a better anticancer effect of sorafenib in patients with diabetes.
Authors: Issam Ben Sahra; Yannick Le Marchand-Brustel; Jean-François Tanti; Frédéric Bost Journal: Mol Cancer Ther Date: 2010-05-04 Impact factor: 6.261
Authors: Tomomi Kamba; Betty Y Y Tam; Hiroya Hashizume; Amy Haskell; Barbara Sennino; Michael R Mancuso; Scott M Norberg; Shaun M O'Brien; Rachel B Davis; Lori C Gowen; Keith D Anderson; Gavin Thurston; Shuji Joho; Matthew L Springer; Calvin J Kuo; Donald M McDonald Journal: Am J Physiol Heart Circ Physiol Date: 2005-09-19 Impact factor: 4.733
Authors: Mustafa S Ascha; Ibrahim A Hanouneh; Rocio Lopez; Tarek Abu-Rajab Tamimi; Ariel F Feldstein; Nizar N Zein Journal: Hepatology Date: 2010-06 Impact factor: 17.425
Authors: Valter Donadon; Massimiliano Balbi; Michela Ghersetti; Silvia Grazioli; Antonio Perciaccante; Giovanni Della Valentina; Rita Gardenal; Maria Dal Mas; Pietro Casarin; Giorgio Zanette; Cesare Miranda Journal: World J Gastroenterol Date: 2009-05-28 Impact factor: 5.742
Authors: D T Silverman; M Schiffman; J Everhart; A Goldstein; K D Lillemoe; G M Swanson; A G Schwartz; L M Brown; R S Greenberg; J B Schoenberg; L M Pottern; R N Hoover; J F Fraumeni Journal: Br J Cancer Date: 1999-08 Impact factor: 7.640
Authors: Agnieszka Karbownik; Anna Stachowiak; Hanna Urjasz; Katarzyna Sobańska; Agnieszka Szczecińska; Tomasz Grabowski; Joanna Stanisławiak-Rudowicz; Anna Wolc; Edmund Grześkowiak; Edyta Szałek Journal: Pharmacol Rep Date: 2020-01-08 Impact factor: 3.024
Authors: Giorgia Marisi; Alessandro Cucchetti; Paola Ulivi; Matteo Canale; Giuseppe Cabibbo; Leonardo Solaini; Francesco G Foschi; Serena De Matteis; Giorgio Ercolani; Martina Valgiusti; Giovanni L Frassineti; Mario Scartozzi; Andrea Casadei Gardini Journal: World J Gastroenterol Date: 2018-09-28 Impact factor: 5.742